Compare Lowe`s Companies Inc (LOW) vs TG Therapeutics Inc (TGTX) Price & Performance

Lowe's (LOW) trades at $186.00, up 2.46% with recent earnings beats but faces bearish technical signals. The stock shows solid fundamentals with a P/E of 15.96 and net margin of 7.35%, though revenue has declined from $96.2B in 2022 to $83.7B in 2025. Recent news highlights drone delivery innovation with DoorDash and Alphabet, while the home improvement sector faces macroeconomic headwinds.

Wall Street maintains a bullish consensus with a $244.09 price target (31 Buy, 19 Hold, 1 Sell), representing 31% upside potential. Key risks include housing market stagnation and competitive pressure from Home Depot. The negative shareholder equity position requires monitoring, but consistent dividend payments and operational cash flow strength provide stability.

TG Therapeutics (TGTX) trades at $55.37, up 4.57% today, but faces a bearish technical signal with recent earnings misses. Strong revenue growth is driven by BRIUMVI, with 2026 guidance raised to $950 million, though profitability is pressured by investments. A shareholder investigation and volatile cash flows add uncertainty, while analyst consensus remains bullish with an $80.50 price target.

The outlook hinges on BRIUMVI's market share gains and subcutaneous formulation progress, offering upside if execution succeeds. Risks include the fiduciary investigation, competitive pressures, and reliance on a single product. The stock presents a high-risk, high-reward opportunity, with current valuation reflecting growth expectations but vulnerable to setbacks.